Gemcitabine


Published: June 11, 2009
Abstract Views: 144
PDF: 163
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Gemcitabine (2',2'-difluorodeoxy- cytidine, dFdC) is an analog of deoxycytidine. It is transformed to the active triphosphate (dFdCTP) after intracellular phosphorylation. Gemcitabine monophosphate is inserted into the DNA and inhibits DNA elongation as a false nucleotide. In contrast to other antimetabolites, an additional, altered nucleotide is inserted behind dFdC inhibiting repair mechanisms (masked chain termination).

Supporting Agencies


Tani, M., Alinari, L., Broccoli, A., Derenzini, E., Fina, M., Gandolfi, L., Marchi, E., Pellegrini, C., Stefoni, V., Venturini, F., & Zinzani, P. (2009). Gemcitabine. Hematology Meeting Reports (formerly Haematologica Reports), 3(1). https://doi.org/10.4081/hmr.v3i1.542

Downloads

Citations